Dicerna Pharmaceuticals is a US-based biopharmaceutical company that specializes in developing treatments for liver diseases and cancers using their proprietary RNA interference technology platform. Its main development program is DCR-PH1, which aims to treat primary hyperoxaluria type 1 (PH1) and other rare inherited diseases that involve genes expressed in the liver.